Background. Hypercoagulability may be an important contributor to the pathophysiology of atherosclerosis and atherothrombosis. As thrombin fulfills a central role in coagulation and links to several cellular mechanisms involved in arterial disease, we hypothesized that thrombin generation is associated with cardiovascular events in elderly patients. Methods. We studied the relationship between plasma thrombin generation and incident coronary heart disease (CHD) and stroke in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). From this multicenter prospective cohort, 4,932 samples of subjects (70-82 years) with pre-existing vascular disease or risk factors were available for thrombin generation measurements. Results. Within the 3.2 years of follow-up incident stroke and CHD was observed in 227 and 545 subjects, respectively. Baseline thrombin generation was significantly decreased in subjects with incident stroke compared with subjects without: normalized peak height 71.1 ± 40.8% versus 82.3 ± 44.9%, p = .0002, and normalized endogenous thrombin potential 79.1 ± 23.3% versus 87.0 ± 24.8%, p < .0001 (mean and SDs). Thrombin generation was independently and inversely associated with stroke risk: hazard ratio 0.71 (95%CI: 0.60-0.85), 0.68 (95%CI: 0.58-0.79), for normalized peak height and normalized endogenous thrombin potential, respectively (all p < .001). In subjects with incident CHD, thrombin generation was comparable to subjects without a coronary event. Only an increased normalized peak height was significantly associated with incident CHD (hazard ratio 1.17 [95% CI: 1.06-1.28], p = .002). Conclusions. We demonstrate that a delayed and decreased thrombin generation is a strong and independent predictor for stroke in elderly people at increased risk of vascular disease. However, no convincing consistent association could be demonstrated between thrombin generation and incident CHD.
Arterial disease remains the leading cause of death and disability in older people (1) (2) (3) . Besides the conventional cardiovascular risk factors, experimental as well as a small number of clinical studies suggest a contribution of hypercoagulability to the pathophysiology of arterial disease (4, 5) . In older age, it has been demonstrated that an increased coagulation activity, as well as a disturbed fibrinolysis, assessed by plasma levels of fibrinogen, D-dimer, and tissue plasminogen activator antigen, are predictors of future vascular events (both coronary heart disease [CHD] and stroke) (6) (7) (8) .
In the coagulation process, thrombin is the key enzyme with a multifaceted character. Besides regulating a diversity of hemostatic functions, thrombin serves as a potent cell-signaling molecule, activating several complex processes that are involved in the development and progression of arterial disease (4, 5) . Thrombin generation assays, which assess the potential of a plasma to form thrombin, can provide useful information about the prothrombotic tendency of a patient (9) . Up to now only a limited number of studies have investigated the relationship between thrombin generation and cardiovascular diseases, however, effects on thrombin generation are seen that both connect to atherosclerosis (10, 11) , and atherothrombosis (12) (13) (14) (15) .
Over the past years, there has been increasing interest in the use of circulating markers, including hemostatic factors, to extent the clinical prediction of cardiovascular disease and atherothrombotic events (16) . Although recent studies suggest an overlap between cerebral and coronary atherosclerosis (17, 18) , vascular beds are known to differ from one to another in endothelial cell expression of hemostatic factors (19) . Investigating the relationship between thrombin generation and future atherothrombotic events, both myocardial infarction (MI) and stroke, can establish whether the associations are comparable between these different vascular beds. This may help improve our current understanding of the pathophysiological mechanisms leading to thrombosis at different vascular sites.
The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) was a double blind, randomized, placebocontrolled trial designed to determine whether treatment with pravastatin reduced the risk of cardiovascular disease in elderly subjects with preexisting vascular disease or at high risk of developing vascular disease (20, 21) . By further analysis of the large prospective clinical dataset from the PROSPER, we aimed to determine the associations between thrombin generation and the risk of MI and stroke in the elderly, using the Calibrated Automated Thrombogram (CAT) method.
Materials and methods

Overview of Study Design and Participants
The PROSPER study has been described in detail elsewhere (20, 21) . Briefly, the trial showed that 3.2 years of lipid-lowering therapy with pravastatin 40 mg/d significantly reduced the risk of MI, but not stroke, in elderly subjects with preexisting vascular disease (coronary, cerebral, or peripheral) or with major risk factors such as smoking, diabetes, or hypertension. Three European coordinating centers (Glasgow, Scotland, Cork, Ireland, and Leiden, The Netherlands) collaborated in the project, and subjects were screened and enrolled between December 1997 and May 1999. All participants were clinically examined at baseline before randomization, which included venous blood collection from the antecubital vein.
In the original PROSPER trial, 5,804 individuals (2,806 men; 2,998 women), 70-82 years of age, were randomly assigned to pravastatin or placebo (2,520 from UK, 2,184 from Ireland, and 1,100 from the Netherlands), and the mean follow-up was 3.2 years (range 2.8-4.0). All subjects provided written informed consent. The study was approved by the institutional review boards of all centers and was conducted according to the principles of the Declaration of Helsinki. All data were processed and analyzed at the Robertson Centre for Biostatistics, University of Glasgow (Glasgow, UK).
From the original study sample of 5,804 individuals, 105 of were excluded as taking warfarin at baseline; of the remaining 5,699 patients 4,932 had plasma samples available for thrombin generation measurements. The primary outcome in our study was the combined endpoint of definite or suspect death from CHD, nonfatal MI, and fatal plus nonfatal stroke. Secondary outcomes included examination of the coronary and cerebrovascular components separately: CHD death and nonfatal MI, fatal plus nonfatal total stroke (Ischemic, hemorrhagic, and undefined), and fatal plus nonfatal ischemic stroke. Additionally, analyses of all-cause and vascular mortality were included in the study. Strokes were categorized as ischemic or hemorrhagic on the basis of neuroimaging (computed tomography or magnetic resonance imaging) or postmortem. Neurologic deficit lasting ≥24 hours or leading to death, without neuroimaging or postmortem data available were categorized as undefined strokes. Further details about the inclusion and exclusion characteristics and study endpoints are given in the PROSPER design paper.
Thrombin Generation
Baseline, pretreatment, citrated blood samples (stored at −80 °C) were used for thrombin generation analysis (22) . According to our previously described standardized protocol (23), we measured thrombin generation in human platelet-poor plasma by means of the validated CAT method (Thrombinoscope BV, Maastricht, The Netherlands). The CAT method employs a low affinity fluorogenic substrate for thrombin (Z-Gly-Gly-Arg-AMC) to continuously monitor thrombin activity in clotting plasma. Measurements were conducted in 80 μL human platelet-poor plasma in a total volume of 120 μL (20 μL fluorogenic substrate, Calcium chloride (FluCa) and 20 μL trigger reagent). The following experimental conditions were used: 1 pM tissue factor (TF) with 4 μM phospholipids at 20:20:60 mol% PS:PE:PC, and 5 pM TF with 4 µM phospholipids (All CAT-reagents were obtained from Thrombinoscope BV). Measurements were performed after 10 minutes of preheating at 37 °C in the fluorometer. In order to correct for innerfilter effects and substrate consumption, each thrombin generation measurement was calibrated against the fluorescence curve obtained in a sample from the same plasma (80 μL), added with a fixed amount of thrombin-α2-macroglobulin complex (20 μL Thrombin Calibrator) and 20 μL FluCa. Fluorescence was read in a Fluoroskan Ascent reader (Thermo Labsystems OY, Helsinki, Finland) equipped with a 390/460 filter set and thrombin generation curves were calculated with the Thrombinoscope software (Thrombinoscope BV).
Statistical Analysis
Summary statistics are reported as mean ± SD for continuous variables and as number (%) for categorical variables. The following thrombin generation parameters were chosen a-priori to be the primary predictor variables: normalized endogenous thrombin potential (nETP), normalized peak height (nPeak), lag time, and time to tail (Figure 1 ). The lag time reflects the initiation phase of coagulation and approximates the clotting time. The peak height is the maximum amount of thrombin formed and the endogenous thrombin potential (area under de curve) corresponds to the total amount of thrombin formed. The time to tail is the time until the end point of thrombin generation, reflecting the termination phase of coagulation. To obtain acceptable interassay variations, the timeindependent parameters ETP (area under the curve) and peak height (the maximum amount of thrombin formed) were normalized based on platelet-poor normal pooled plasma obtained from healthy volunteers, the latter used as a reference (24) . Data are expressed as % of normal pooled plasma. Where necessary (eg lag time and time to tail), continuous variables were transformed logarithmically to give a near-normal distribution of data for parametric analysis.
Cox proportional hazards models were used to investigate the associations between thrombin generation and all primary and secondary endpoints. Adjustment for covariates was according to the following three models: Model 1 only adjusted for country, Model 2 additionally adjusted for randomized treatment and conventional cardiovascular risk factors (age, sex, systolic blood pressure, diastolic blood pressure, current smoker, any alcohol consumption, history of diabetes, and history of vascular disease), and Model 3 additionally adjusted for interleukin-6 (IL-6) and C-reactive protein (CRP). Results are reported as hazard ratios (HRs) with 95% confidence intervals (95% CI) and corresponding p values. All HRs (95% CI) represent a change of one SD in the placebo population and p < .05 were considered statistically significant. Alcohol consumption was self-reported and analyzed as any versus none. Diabetes at baseline was defined as self-reported diagnosis and hypertension as currently receiving anti-hypertensive drug treatment. History of vascular disease was defined by physician-diagnosed stable angina, intermittent claudication, stroke, transient ischemic attack, MI, arterial surgery, or amputation for vascular disease more than 6 months before study entry. At baseline CRP was measured with an automated particleenhanced immunoturbidimetric assay (Roche UK). IL-6 was measured at baseline with an enzyme-linked immunosorbent assay from R&D systems, as previously reported (25) .
To determine the influence of treatment randomization (pravastatin or placebo) on thrombin generation measurements interaction testing was performed. Finally, we conducted a sensitivity analysis, excluding all Irish subjects to evaluate the potential impact of the Irish cohort on study results.
RESULTS
The clinical characteristics of the 4,932 patients are summarized in Table 1 . The mean age of the study participants was 75.3 years and 52.6% was female. Table 2 compares thrombin generation levels between subjects with preexisting vascular disease and subjects without. Analysis of the component parts of history of vascular diseases revealed that in subjects with a history of CHD (MI, percutaneous transluminal coronary angioplasty, coronary artery bypass surgery, angina, or nitrates) thrombin generation levels were significantly increased compared to subjects without preexisting CHD (nETP 89.5 ± 24.9% vs 85.2 ± 24.5%, p < .0001, and nPeak 88.3 ± 47.6% vs 78.6 ± 43.0%, p < .0001; mean and SD). In contrast, in subjects with preexisting cerebrovascular disease (stroke or transient ischemic attack) or peripheral arterial disease (claudication, peripheral arterial surgery, or amputation for vascular disease) thrombin generation was not significantly different compared with subjects without a history of cerebrovascular or peripheral arterial disease ( Table 2) .
The associations between the 1 and 5 pM TF thrombin generation measurements and primary and secondary outcome measures calculated for the total PROSPER cohort are shown in Table 3 (1 pM TF data) and Supplementary Table 1 (5 pM TF data). The HRs are demonstrated for individual thrombin generation variables adjusted according to three cox proportional hazards models. Overall, HRs were attenuated only slightly by the inclusion of treatment and conventional risk factors (model 2), and the inflammatory markers, IL-6 and CRP (model 3). HRs did not change when multivariate analysis was repeated with history of vascular disease divided into its components parts (history of CHD, peripheral arterial disease, or stroke/ transient ischemic attack) and history of hypertension added to the model. For the discussion of the study results we will focus on the HRs adjusted for all covariates (model 3).
Thrombin Generation and Primary Outcome
The primary outcome was the combined endpoint of definite or suspect death from CHD, nonfatal MI, and fatal plus nonfatal stroke. Within the 3.2 years of follow-up, there were 744 (15.1%) subjects that reached a primary endpoint. We found no significant association between thrombin generation and the primary endpoint in general, for both the 1 (Table 3 ) and 5 pM TF trigger (Supplementary Table 1 ).
Thrombin Generation and CHD Risk
The incidence rate of CHD death and nonfatal MI was 545 (11.1%) within the 3.2 years of follow-up. Mean thrombin generation levels at baseline were comparable between subjects with and without a coronary event during follow-up (nPeak 84.3 ± 51.9% vs 81.4 ± 43.8%, and nETP 86.6 ± 24.5% vs 86.9 ± 27.1%; mean and SD). We found a limited association between thrombin generation and CHD risk ( 
Thrombin Generation and Stroke Risk
During the 3.2 years of follow-up, 227 (4.6%) subjects had incident stroke, in 156 (69%) of which ischemic etiology was confirmed. Baseline thrombin generation was significantly decreased in subjects with a cerebrovascular event during follow-up compared with subjects with no event (nPeak 71.1 ± 40.8% vs 82.3 ± 44.9%, p = .0002, and nETP 79.1 ± 23.3% vs 87.0 ± 24.8%, p < .0001; mean and SDs). Moreover, Table 3 shows that thrombin generation was independently and inversely associated with total stroke risk (ischemic, hemorrhagic, and undefined) as well as confirmed ischemic stroke risk. The HRs for total and ischemic stroke were comparable, and although the negative predictive value of the 1 pM TF thrombin generation parameters was stronger, the associations remained significant when triggering with 5 pM TF (except LogTtT for ischemic stroke; Supplementary Table 1) . For both TF concentrations the nETP was the parameter with the highest negative predictive value in relation to fatal and nonfatal total and ischemic stroke risk.
Thrombin Generation and Atrial Fibrillation
Subjects with electrocardiographic evidence of atrial fibrillation were excluded at baseline. During the course of the study a total of 453 (9.19%) subjects developed atrial fibrillation. No significant association was demonstrated between baseline thrombin generation and incident atrial fibrillation (data not shown). Moreover, in a subanalysis we observed no effect of exclusion of subjects with incident atrial fibrillation on the associations between thrombin generation and stroke risk.
Thrombin Generation and Mortality
Within the 3.2 years of follow-up, the incidence rates of all-cause and vascular mortality were 504 (10.2%) and 234 (4.9%), respectively. Neither all-cause mortality nor vascular mortality was significantly associated with thrombin generation measured at 1 (Table 3) and 5 pM TF (Supplementary Table 1 ). As shown in both tables, significant associations were found between some of the thrombin generation parameters and all-cause and vascular mortality (models 1 and 2). However, after additional adjustment for IL-6 and CRP they lost their significance, suggesting inflammation to be contributing to the increased thrombin generation potential.
Treatment Allocation Interaction
Interaction testing was performed to determine whether thrombin generation measurements were influenced by allocation of subjects to pravastatin or placebo. However, no significant interactions of treatment randomization were demonstrated with any of the thrombin generation parameters.
Discussion
We report the largest prospective study to date (n = 4,932) of the associations of thrombin generation with incident cardiovascular disease (CHD and stroke), in an older population with baseline vascular Notes: Results of continuous variables are given as mean with SD. Categorical variables are numbers with percentages (n, %). CABG = coronary artery bypass graft; CRP = C-reactive protein; CHD = coronary heart disease; IL-6 = interleukin 6; MI = myocardial infarction; PTCA = percutaneous transluminal coronary angioplasty; TIA = transient ischemic attack. disease or vascular risk factors, recruited from three European countries. Despite the fact that a hypercoagulable state affects the entire body, in many diseases thrombotic and bleeding complications show a predilection to specific vascular sites. We observed no significant association of thrombin generation with the primary endpoint (combined endpoint of fatal and nonfatal MI plus stroke). However, when analyzing the vascular endpoints separately, the directions of the association of thrombin generation with CHD and stroke appeared different. Thrombin generation was consistently inversely associated with stroke risk (both total and ischemic stroke; Table 3 and  Supplementary Table 1) . On the contrary, most thrombin generation parameters showed no significant association with CHD, except for a positive predictive value for the nPeak, measured at 1 pM TF (HR 1.17 [95% CI: 1.06-1.28], p = .002; Table 3 ).
Different studies demonstrated that during and also months after an acute coronary event, thrombin generation was significantly increased compared to healthy controls and stable CHD patients (12) (13) (14) (15) . In this study, we showed that subjects with a history of CHD, but not other forms of preexisting vascular disease, had significantly higher baseline levels of nPeak and nETP (Table 2) . Although these data were unadjusted for potential confounders they do give an indication of the baseline associations, suggesting preexisting CHD to be associated with an enhanced thrombin generation.
There are only few previous studies that have reported on the associations of thrombin generation with CHD. In a previous study of patients with acute MI, a trend of an inverse association of thrombin generation with recurrent cardiovascular (mostly CHD) events was demonstrated. In conjunction with an elevated D-dimer level a significant inverse association for recurrence was obtained (OR 5.8) (13) . In a recent case-control study of persons with a previous (3-9 months) acute MI (the Glasgow MI study), cases had a significantly increased thrombin generation compared to controls (14) . A subsequent prospective study of this population, aged 24-64 years (The Glasgow MONICA Study), observed that a significantly prolonged lag time and lower peak height and ETP were associated with first CVD (mostly CHD) events. However, after adjustment for classical cardiovascular risk factors these associations were no longer significant [unpublished data]. Interestingly, in this study, the influence of conventional cardiovascular risk factors and inflammatory markers was less pronounced, with no significant effect of adjustment for these potential confounders on the associations of thrombin generation with incident CHD and stroke. Another previous study that investigated the association of thrombin generation with both CHD and ischemic stroke in elderly subjects (≥65 years) showed that thrombin generation was an independent risk factor for ischemic stroke, but not for CHD (26) . In this study, we also observed no overall association of thrombin generation parameters with incident CHD, except for a modest positive association of nPeak, measured at 1 pM TF.
There is only one previous study that investigated the association of thrombin generation with incident stroke (26) . Comparable to our study, Carcaillon and colleagues included elderly subjects (≥65 years). They observed that high thrombin generation levels were associated with an increased risk of ischemic stroke and this positive association appeared to be more relevant in women. On the contrary, in this study we demonstrated a consistent negative association of thrombin generation with incident stroke (total and ischemic stroke), measured both at 1 and 5 pM TF. However, in contrast to our prospective cohort study, including patients with preexisting vascular disease, Carcaillon and colleagues performed a case-cohort study, excluding subjects with previous CHD or stroke.
What are the possible explanations for our finding that decreased thrombin generation in vitro is associated with an increased risk of stroke? We suggest that the most likely explanation is that increased thrombin generation in vivo may precede a decreased thrombin generation in vitro, due to consumption in vivo of plasma cofactors for thrombin generation in vitro. A similar consumption process has been previously proposed for the inverse association of platelet aggregability in vitro with CVD (27) . There are previous reports of an inverse association of thrombin generation in vitro with recurrent CHD (14) ; and with risk of atherothrombotic events in patients with peripheral arterial disease (28) . A consumption explanation may be especially plausible in patients at high risk for stroke, due to organspecific hemostasis: the heterogeneous distribution of coagulation and fibrinolytic factors in the endothelium and its adaptation to various stimuli (19, 29, 30) . The brain differs from the heart in having high internal tissue factor-mediated coagulation activation, and low expression of tissue factor pathway inhibitor, possibly as a protective mechanism against cerebral hemorrhage (31) . It is conceivable that patients at high risk of stroke may have lower thrombin generation in vitro as a consequence of (previous) higher thrombin generation Comparison of 1 pM TF thrombin generation levels between subjects with pre-existing vascular disease and subjects without. Data are expressed as mean with SD and number of events (n). p < .05 were considered statistically significant. CHD = coronary heart disease; nETP = normalized endogenous thrombin potential; nPeak = normalized peak; PAD = peripheral arterial disease; TIA = transient ischemic attack.
*Coronary artery disease defined as a history of myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass surgery, angina, or nitrates. † Peripheral arterial disease defined as a history of claudication, peripheral arterial surgery, or amputation for vascular disease.
in vivo, reflecting upregulated cerebral microcirculation hemostasis in vivo due to small vessel disease, which is a major risk factor for lacunar stroke and hemorrhagic stroke.
There were some limitations to the study. First, the PROSPER population was selected for a randomized controlled trial and consisted of elderly subjects with preexisting vascular risk factors or known vascular disease. Although this is not completely representative for the general elderly population, we consider it a relevant population, since most cardiovascular events occur in such populations. A second limitation is the significant time of storage of plasma samples until thrombin generation analyses. As discussed previously (14) , it cannot be excluded that the storage time has had a potential effect on the stability of the coagulation factors. However, other than a systemic effect on all plasma determinations, we do not expect this to alter the differences in thrombin generation levels between subjects with and without incident cardiovascular disease. If anything, a decline in factor levels would lower the risk association estimates, rather than enlarge any difference. A final limitation relates to the risk of false positive results due to the multiple comparisons. However, we do not think this would explain the apparent differences in risk effects related to vascular bed.
Conclusion
This study presents the results of the largest prospective study to date of the associations of thrombin generation with incident cardiovascular disease (CHD and stroke). We demonstrate that a delayed and decreased thrombin generation is a strong and independent risk factor for stroke in elderly people at increased risk of vascular disease. However, no convincing consistent association could be demonstrated between thrombin generation and CHD. Further prospective studies of thrombin generation and incident stroke and CHD, and systematic reviews of prospective observational studies, are required to clarify these associations with confidence. Notes: Associations for the total PROSPER cohort between 1 pM TF thrombin generation and primary and secondary outcome measures assessed by three cox proportional hazards models. Model 1 adjusted for country. Model 2 additionally adjusted for treatment and conventional cardiovascular risk factors (age, sex, systolic blood pressure, DBP, current smoker, any alcohol consumption, history of diabetes, and history of vascular disease). Model 3 also adjusted for interleukin-6 and C-reactive protein. Results are reported as hazard ratios with 95% confidence intervals (95% CI), representing a change of one SD in the placebo population. p < .05 were considered statistically significant. CHD = coronary heart disease; MI = myocardial infarction; nETP = normalized endogenous thrombin potential; nPeak = normalized peak height; LogLgt = log-transformed lag time; LogTtT = log-transformed time to tail. *denotes p < .05.
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